The SPIN works in close collaboration with National Representatives, gathering the representatives of the national psoriasis groups who participate to the network. We currently surveying in order to include key opinion leaders on atopic dermatitis at the national level.
SPIN National Representatives are in a privileged position to relay the information about SPIN’s projects, surveys and events at the national level. They have kindly accepted to be the national contact for all kind of collaborations, especially to promote the development of the network’s activities and the exchanges on psoriasis and atopic dermatitis all around the world. Each representative is responsible for the coordination of international collaborations between his or her country and the others, and of course for the participation to the projects around psoriasis and atopic dermatitis at the national level.
SPIN National Representatives will be solicited for input in the organisation of the scientific programme of the SPIN Congress taking place every three years. During the Congress, the National Representatives shall meet to foresee the next Congress and to choose the national or regional group that will be responsible for the scientific organisation of the following Congress.
Please find here below the list of SPIN National Representatives (this list shall be updated regularly):
Aomar AMMAR-KHODJA - Algeria
Nélida RAIMONDO- Argentina
Pablo FERNÁNDEZ-PEÑAS - Australia
Patrick BRUNNER- Austria
Uladzimir ADASKEVICH - Belarus
Michel DE LA BRASSINNE - Belgium
Félix ATADOKPEDE - Benin
Juan Carlos DIEZ DE MEDINA - Bolivia
Asja PROHIC - Bosnia and Herzegovina
Luna AZULAY - Brazil
Nikolai TSANKOV - Bulgaria
Fatou BARRO TRAORE - Burkina Faso
Christine MADENGUE - Cameroon
Chih-ho HONG - Canada
Claudia DE LA CRUZ - Chile
Min ZHENG - China
Chih-Hung LEE - Chinese Taipei
Cesar GONZALEZ A. - Colombia
Laura ALVAREZ MORALES - Costa Rica
Abdoulaye SANGHARE - Cote d’Ivoire
Romana CEOVIC - Croatia
Orestes BLANCO G. - Cuba
Jana HERCOGOVA - Czech Republic
Robert GNIADECKI - Denmark
Lars IVERSEN - Denmark
Alexandra ESPINAL - Dominican Republic
Emad ELGAMAL - Egypt
Leana QUINTANILLA - El Salvador
Jaime MARTINEZ LOPEZ - El Salvador
Külli KINGO- Estonia
Tarja MALKONEN - Finland
Carle PAUL - France
Sophie CONIQUET - Gabon
Nino CHIJAVADZE - Georgia
Tsira LEONIDZE - Georgia
Matthias AUGUSTIN - Germany
Christina ANTONIOU - Greece
Mohamed CISSE - Guinea
Ligia RAMOS - Honduras
Patricia MEJIAS - Honduras
Rolland Gyulai - Hungary
Jon Hjaltalin OLAFSSON - Iceland
Alur S. KUMAR - India
Benny E. WIRYADI- Indonesia
Omid ZARGARI - Iran
Brian KIRBY - Ireland
Lev PAVLOVSKY - Israel
Luigi NALDI - Italy
Hidemi NAKAGAWA - Japan
Laith AKKASH - Jordan
Joo Heung Lee- Korea
Nawaf AL MUTAIRI - Kuwait
Andris RUBINS - Latvia
Abdul Ghani KIBBI - Lebanon
Gamal A. DUWEB - Libya
Skaidra VALIUKEVICIENE - Lithuania
Emilija MANASIEVSKA - Macedonia
Azura Mohd AFFANDI- Malaysia
Ousmane FAYE - Mali
Michael BOFFA - Malta
Mamadou BALL - Mauritania
Boris NEDELCIUC - Moldova
Fatima Zahra MERNISSI- Morocco
Phyllis I. SPULS - Netherlands
Jorge NEIRA - Nicaragua
Ousmane KONATE - Niger
Abel Nze ONUNU - Nigeria
Riad MASHAL - Palestine
Giuliana CASTRO - Peru
Maria Lorna FREZ - Philippines
Jacek SZEPIETOWSKI - Poland
Hugo OLIVEIRA - Portugal
Hassan RIAD - Qatar
George-Sorin TIPLICA - Romania
Nikolay POTEKAEV- Russia
Serge SKREK- Russia
Iqbal A. BUKHARI - Saudi Arabia
Fatimata LY - Senegal
Ljiljana MEDENICA - Serbia
Colin THENG - Singapore
Slavomir URBANCEK - Slovakia
Tomaz LUNDER - Slovenia
Luis PUIG - Spain
Mona STAHLE - Sweden
Nikhil YAWALKAR - Switzerland
Fouz HASSAN - Syria
Pravit ASAWANONDA - Thailand
Vincent Pitche - Togo
Nejib DOSS - Tunisia
Mehmet Ali GURER - Turkey
Fayza AL ALI- United Arab Emirates
Christopher GRIFFITHS - United Kingdom
Mark LEBWOHL - United States of America
Oleksandr LITUS - Ukraine
Carlos CARMONA - Uruguay
Erika PAEZ - Venezuela
Alfredo LANDER - Venezuela
Aiman ALSHAMI - Yemen
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Our ambition in a changing landscape of psoriasis treatments.
van de Kerkhof PCM et al.
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat.
2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol..
2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)
see on pubmed
on Atopic Dermatitis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)
see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol.
2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).
see on pubmed
